Balancing the benefits and detriments among women targeted by the Norwegian breast cancer screening program

Journal of Medical Screening

Volumn 23, Issue 4, 2016, Pages 203-209

  Hofvind, Solveig ^a,b   Román, Marta ^a,c   Sebuødegård, Sofie ^a   Falk, Ragnhild S ^c  

^a CANCER REGISTRY OF NORWAY   (Norway)

^b OSLO METROPOLITAN UNIVERSITY   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Breast cancer mortality reduction; Breast neoplasms; False positive results; Mass screening; Over diagnosis

Indexed keywords

AGED; BREAST TUMOR; DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; FEMALE; HEALTH SERVICE; HUMAN; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; MORTALITY; NORWAY; OUTCOME ASSESSMENT; PROCEDURES; STATISTICS AND NUMERICAL DATA;

AGED; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MAMMOGRAPHY; MASS SCREENING; MEDICAL OVERUSE; MIDDLE AGED; MORTALITY; NORWAY; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 85011697866     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: 10.1177/0969141315625088     Document Type: Article

References (30)

1. Bleyer A and Welch HG. Effect of screening mammography on breast cancer incidence. New Engl J Med 2013; 368: 679.
2. Paci E, Broeders M, Hofvind S, et al. The benefits and harms of breast cancer screening. Lancet 2013; 381: 800-801.
3. Broeders M, Moss S, Nystrom L, et al. The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen 2012; 19: 14-25.
4. Lauby-Secretan B, Scoccianti C, Loomis D, et al. Breast-cancer screening-viewpoint of the IARC Working Group. New Engl J Med 2015; 372: 2353-2358.
5. Puliti D, Duffy SW, Miccinesi G, et al. Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen 2012; 19: 42-56.
6. Duffy SW, Chen TH-H, Smith RA, et al. Real and artificial controversies in breast cancer screening. Breast Canc Manage 2013; 2: 9.
7. Paci E. Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. J Med Screen 2012; 19: 5-13.
8. Puliti D, Miccinesi G, Zappa M, et al. Balancing harms and benefits of service mammography screening programs: a cohort study. Breast Canc Res 2012; 14: R9.
9. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 2012; 380: 1778-1786.
10. The Research Council of Norway. Research-based evaluation of the Norwegian Breast Cancer Screening Program-Final Report. Oslo, Norway, May 2015, http://www.forskningsradet.no/prognett-mammografi/Nyheter/30_prosent_redusert_dodelighet_med_Mammografi/1254012233090/ p1226994052839 (accessed 23 November 2015).
11. Mammografiprogrammet-Resultater fra prosessindikatorer, 2006-2013/14. Oslo: Kreftregisteret, 2015, http://kreftregisteret.no/no/Generelt/Publikasjoner/ Mammografiprogrammet/Mammografiprogrammet-Resultater-fra-prosessindikatorer-2006-201314/ (accessed 23 November 2015).
12. Hofvind S, Geller B, Vacek PM, et al. Using the European guidelines to evaluate the Norwegian Breast Cancer Screening Program. Eur J Epidemiol 2007; 22: 447-455.
13. Roman M, Hubbard RA, Sebuodegard S, et al. The cumulative risk of falsepositive results in the Norwegian Breast Cancer Screening Program: updated results. Cancer 2013; 119: 3952-3958.
14. Hofvind S, Ursin G, Tretli S, et al. Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program. Cancer 2013; 119: 3106-3112.
15. Weedon-Fekjaer H, Romundstad PR and Vatten LJ. Modern mammography screening and breast cancer mortality: population study. Br Med J 2014; 348: g3701.
16. Kalager M, Zelen M, Langmark F, et al. Effect of screening mammography on breast-cancer mortality in Norway. New Engl J Med 2010; 363: 1203-1210.
17. Falk RS, Hofvind S, Skaane P, et al. Overdiagnosis among women attending a population-based mammography screening program. Int J Canc 2013; 133: 705-712.
18. Kalager M, Adami HO, Bretthauer M, et al. Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med 2012; 156: 491-499.
19. Zahl PH and Maehlen J. Overdiagnosis of breast cancer after 14 years of mammography screening. Tidsskrift for den Norske laegeforening 2012; 132: 414-417.
20. Lund E, Mode N, Waaseth M, et al. Overdiagnosis of breast cancer in the Norwegian Breast Cancer Screening Program estimated by the Norwegian Women and Cancer cohort study. BMC Canc 2013; 13: 614.
21. Sorum R, Hofvind S, Skaane P, et al. Trends in incidence of ductal carcinoma in situ: the effect of a population-based screening programme. Breast 2010; 19: 499-505.
22. Cancer Registry of Norway. Cancer in Norway 2012-Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway, 2014.
23. Moller B, Weedon-Fekjaer H, Hakulinen T, et al. The influence of mammographic screening on national trends in breast cancer incidence. Eur J Canc Prev 2005; 14: 117-128.
24. Duffy SW and Parmar D. Overdiagnosis in breast cancer screening: the importance of length of observation period and lead time. Breast Canc Res 2013; 15: R41.
25. Moss SM, Nystrom L, Jonsson H, et al. The impact of mammographic screening on breast cancer mortality in Europe: a review of trend studies. J Med Screen 2012; 19: 26-32.
26. Olsen AH, Lynge E, Njor SH, et al. Breast cancer mortality in Norway after the introduction of mammography screening. Int J Canc 2013; 132: 208-214.
27. Hofvind S, Sakshaug S, Ursin G, et al. Breast cancer incidence trends in Norway-explained by hormone therapy or mammographic screening? Int J Canc 2012; 130: 2930-2938.
28. Weedon-Fekjaer H, Bakken K, Vatten LJ, et al. Understanding recent trends in incidence of invasive breast cancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use. Br Med J 2012; 344: e299.
29. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. Jama 2002; 288: 321-333.
30. Lynge EB, Njor T, Olsen S, et al. Mammography activity in Norway 1983 to 2008. Acta Oncol 2011; 50: 1062-1067.